30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now
United States Biotechnology & Medical Research

Deciphera Pharmaceuticals Inc (DCPH)

Track

Stock chart
Ticker: DCPH Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
Kelly Thomas Patrick
Chief Financial Officer
1 sale — total 47,009 USD
Sale 16 Feb 2024
Value US$4,385,686.03 | Price 451.22 | Shares 27,271
Sale 16 Feb 2024
Value US$4,919,931.87 | Price 306.65 | Shares 19,010
Sale 16 Feb 2024
Value US$35,405.10 | Price 15.62 | Shares 2,267
Sale 16 Feb 2024
Value US$35,405.10 | Price 15.62 | Shares 2,267
Sale 16 Jan 2024
Value US$23,498.96 | Price 14.47 | Shares 1,624
Sale 16 Jan 2024
Value US$35,233.72 | Price 14.47 | Shares 2,435
Sale 16 Jan 2024
Value US$35,233.96 | Price 14.47 | Shares 2,435
Sale 16 Jan 2024
Value US$23,498.79 | Price 14.47 | Shares 1,624
Sale 13 Dec 2023
Value US$42,904.94 | Price 15.37 | Shares 2,792
Sale 13 Dec 2023
Value US$42,904.94 | Price 15.37 | Shares 2,792
Sale 13 Dec 2023
Value US$25,540.12 | Price 15.37 | Shares 1,662
Sale 13 Dec 2023
Value US$471,216.75 | Price 15.37 | Shares 30,664
Sale 13 Dec 2023
Value US$26,538.98 | Price 15.37 | Shares 1,727
Planned sale 30 Nov 2023
Value US$223,755.01 | Price 12.57 | Shares 17,801
Proposed sale 30 Nov 2023
Value US$223,755.48 | Price 12.57 | Shares 17,801
Sale 30 Oct 2023
Value US$16,908.76 | Price 12.02 | Shares 1,407
Sale 30 Oct 2023
Value US$259,255.68 | Price 12.02 | Shares 21,573
Sale 30 Oct 2023
Value US$16,908.76 | Price 12.02 | Shares 1,407
Sale 30 Oct 2023
Value US$28,361.54 | Price 12.02 | Shares 2,360
Sale 30 Oct 2023
Value US$27,832.76 | Price 12.02 | Shares 2,316
Sale 2 Oct 2023
Value US$37,304.56 | Price 12.68 | Shares 2,942
Sale 16 Jun 2023
Value US$23,834.98 | Price 14.40 | Shares 1,655
Planned sale 16 Jun 2023
Value US$17,829.43 | Price 14.40 | Shares 1,238
Planned sale 16 Jun 2023
Value US$23,834.98 | Price 14.40 | Shares 1,655
Sale 16 Jun 2023
Value US$23,834.98 | Price 14.40 | Shares 1,655
Sale 16 Jun 2023
Value US$17,829.43 | Price 14.40 | Shares 1,238
Buy 8 Jun 2023
Value US$138,828.00 | Price 13.88 | Shares 10,000
Buy 10 May 2023
Value US$152,416.00 | Price 13.86 | Shares 11,000
Planned sale 21 Mar 2023
Value US$116,781.75 | Price 15.57 | Shares 7,500
Sale 16 Feb 2023
Value US$17,499.74 | Price 15.10 | Shares 1,159
Sale 16 Feb 2023
Value US$20,685.63 | Price 15.10 | Shares 1,370
Sale 16 Feb 2023
Value US$20,685.63 | Price 15.10 | Shares 1,370
Sale 16 Feb 2023
Value US$14,661.13 | Price 15.10 | Shares 971
Sale 16 Feb 2023
Value US$17,499.74 | Price 15.10 | Shares 1,159
Planned sale 14 Feb 2023
Value US$480,720.00 | Price 16.00 | Shares 30,045
Buy 24 Jan 2023
Value US$29,999,988.00 | Price 18.00 | Shares 1,666,666
Planned sale 17 Jan 2023
Value US$51,042.84 | Price 21.24 | Shares 2,403
Planned sale 17 Jan 2023
Value US$34,049.80 | Price 21.24 | Shares 1,603
Sale 17 Jan 2023
Value US$51,042.84 | Price 21.24 | Shares 2,403
Sale 17 Jan 2023
Value US$34,049.80 | Price 21.24 | Shares 1,603
Sale 17 Jan 2023
Value US$51,042.84 | Price 21.24 | Shares 2,403
Sale 3 Oct 2022
Value US$48,454.51 | Price 18.73 | Shares 2,587
Sale 16 Jun 2022
Value US$19,006.00 | Price 10.75 | Shares 1,768
Sale 16 Jun 2022
Value US$19,006.00 | Price 10.75 | Shares 1,768
Planned sale 16 Jun 2022
Value US$19,006.00 | Price 10.75 | Shares 1,768
Planned sale 16 Jun 2022
Value US$14,093.25 | Price 10.75 | Shares 1,311
Sale 16 Jun 2022
Value US$13,953.50 | Price 10.75 | Shares 1,298
Buy 29 Apr 2022
Value US$14,789,780.00 | Price 10.00 | Shares 1,478,978
Sale 16 Feb 2022
Value US$8,905.20 | Price 9.05 | Shares 984
Sale 16 Feb 2022
Value US$10,371.30 | Price 9.05 | Shares 1,146
Sale 16 Feb 2022
Value US$12,362.30 | Price 9.05 | Shares 1,366
Sale 16 Feb 2022
Value US$12,380.40 | Price 9.05 | Shares 1,368
Sale 16 Feb 2022
Value US$10,371.30 | Price 9.05 | Shares 1,146
Planned sale 4 Oct 2021
Value US$88,199.03 | Price 33.17 | Shares 2,659
Planned sale 3 May 2021
Value US$14,025.00 | Price 46.75 | Shares 300
Planned sale 3 May 2021
Value US$354,718.21 | Price 46.07 | Shares 7,700
Planned sale 20 Apr 2021
Value US$77,513.71 | Price 45.60 | Shares 1,700
Planned sale 19 Apr 2021
Value US$60,662.03 | Price 46.66 | Shares 1,300
Planned sale 19 Apr 2021
Value US$184,518.00 | Price 46.13 | Shares 4,000
Planned sale 12 Apr 2021
Value US$230,040.48 | Price 44.09 | Shares 5,217
Planned sale 12 Apr 2021
Value US$414,370.12 | Price 43.70 | Shares 9,483
Planned sale 1 Apr 2021
Value US$42,328.41 | Price 46.72 | Shares 906
Planned sale 1 Apr 2021
Value US$228,169.37 | Price 45.69 | Shares 4,994
Planned sale 1 Apr 2021
Value US$94,074.33 | Price 44.80 | Shares 2,100
Planned sale 1 Mar 2021
Value US$49,324.29 | Price 44.68 | Shares 1,104
Planned sale 1 Mar 2021
Value US$302,982.66 | Price 43.94 | Shares 6,896
Sale 16 Feb 2021
Value US$6,450.84 | Price 48.87 | Shares 132
Sale 16 Feb 2021
Value US$24,825.96 | Price 48.87 | Shares 508
Sale 16 Feb 2021
Value US$25,607.88 | Price 48.87 | Shares 524
Planned sale 1 Feb 2021
Value US$36,770.00 | Price 45.96 | Shares 800
Planned sale 1 Feb 2021
Value US$206,187.51 | Price 45.64 | Shares 4,518
Planned sale 1 Feb 2021
Value US$118,914.78 | Price 44.34 | Shares 2,682
Planned sale 15 Jan 2021
Value US$30,666.00 | Price 51.11 | Shares 600
Planned sale 15 Jan 2021
Value US$321,373.44 | Price 50.21 | Shares 6,400
Planned sale 4 Jan 2021
Value US$160,294.29 | Price 57.37 | Shares 2,794
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2024-02-20 2024-02-16 S Sale
2.9
Kelly Thomas Patrick

Chief Financial Officer

Officer
27,271 +17.7%
451.22
US$4,385,686 		27,271 +17.7% 451.22 US$4,385,686
2024-02-20 2024-02-16 S Sale
2.7
Sherman Matthew L

EVP & Chief Medical Officer

Officer
19,010 +24.4%
306.65
US$4,919,932 		19,010 +24.4% 306.65 US$4,919,932
2024-02-20 2024-02-16 S Sale
2.8
Pitman Jama

SVP, Chief Development Officer

Officer
77,600 -26.8%
226.02
US$4,658,156 		77,600 -26.8% 226.02 US$4,658,156
2024-02-20 2024-02-16 S Sale
2.3
Martin Daniel C.

Chief Commercial Officer

Officer
2,267 -4.0%
15.62
US$35,405 		2,267 -4.0% 15.62 US$35,405
2024-01-18 2024-01-16 S Sale
2.8
Pitman Jama

SVP, Chief Development Officer

Officer
1,624 -3.1%
14.47
US$23,499 		1,624 -3.1% 14.47 US$23,499
2024-01-18 2024-01-16 S Sale
2.7
Sherman Matthew L

EVP & Chief Medical Officer

Officer
2,435 -2.5%
14.47
US$35,234 		2,435 -2.5% 14.47 US$35,234
2024-01-18 2024-01-16 S Sale
2.9
Kelly Thomas Patrick

Chief Financial Officer

Officer
2,435 -3.6%
14.47
US$35,234 		2,435 -3.6% 14.47 US$35,234
2024-01-18 2024-01-16 S Sale
2.3
Martin Daniel C.

Chief Commercial Officer

Officer
1,624 -3.3%
14.47
US$23,499 		1,624 -3.3% 14.47 US$23,499
2023-12-14 2023-12-13 S Sale
2.9
Kelly Thomas Patrick

Chief Financial Officer

Officer
2,792 -3.9%
15.37
US$42,905 		2,792 -3.9% 15.37 US$42,905
2023-12-14 2023-12-13 S Sale
2.7
Sherman Matthew L

EVP & Chief Medical Officer

Officer
2,792 -2.8%
15.37
US$42,905 		2,792 -2.8% 15.37 US$42,905
2023-12-14 2023-12-13 S Sale
2.8
Pitman Jama

See Remarks

Officer
1,662 -3.1%
15.37
US$25,540 		1,662 -3.1% 15.37 US$25,540
2023-12-14 2023-12-13 S Sale
3.7
Hoerter Steven L.

President and CEO

Executive Director
30,664 -29.6%
15.37
US$471,217 		30,664 -29.6% 15.37 US$471,217
2023-12-14 2023-12-13 S Sale
2.3
Martin Daniel C.

Chief Commercial Officer

Officer
1,727 -3.4%
15.37
US$26,539 		1,727 -3.4% 15.37 US$26,539
2023-12-01 2023-11-30 PlS Planned sale
2.3
Martin Daniel C.

Chief Commercial Officer

Officer
17,801 -28.2%
12.57
US$223,755 		17,801 -28.2% 12.57 US$223,755
2023-11-30 2023-11-30 PrS Proposed sale
2.3
Martin Daniel C.

Officer

Officer
17,801
12.57
US$223,755 		17,801 12.57 US$223,755
2023-10-31 2023-10-30 S Sale
2.3
Martin Daniel C.

Chief Commercial Officer

Officer
1,407 -2.2%
12.02
US$16,909 		1,407 -2.2% 12.02 US$16,909
2023-10-31 2023-10-30 S Sale
3.7
Hoerter Steven L.

President and CEO

Executive Director
21,573 -34.5%
12.02
US$259,256 		21,573 -34.5% 12.02 US$259,256
2023-10-31 2023-10-30 S Sale
2.8
Pitman Jama

See Remarks

Officer
1,407 -2.8%
12.02
US$16,909 		1,407 -2.8% 12.02 US$16,909
2023-10-31 2023-10-30 S Sale
2.7
Sherman Matthew L

EVP & Chief Medical Officer

Officer
2,360 -2.5%
12.02
US$28,362 		2,360 -2.5% 12.02 US$28,362
2023-10-31 2023-10-30 S Sale
2.9
Kelly Thomas Patrick

Chief Financial Officer

Officer
2,316 -3.5%
12.02
US$27,833 		2,316 -3.5% 12.02 US$27,833
2023-10-04 2023-10-02 S Sale
2.7
Sherman Matthew L

EVP & Chief Medical Officer

Officer
2,942 -3.4%
12.68
US$37,305 		2,942 -3.4% 12.68 US$37,305
2023-06-21 2023-06-16 S Sale
2.9
Kelly Thomas Patrick

Chief Financial Officer

Officer
1,655 -2.8%
14.40
US$23,835 		1,655 -2.8% 14.40 US$23,835
2023-06-21 2023-06-16 PlS Planned sale
2.3
Martin Daniel C.

Chief Commercial Officer

Officer
1,238 -2.1%
14.40
US$17,829 		1,238 -2.1% 14.40 US$17,829
2023-06-21 2023-06-16 PlS Planned sale
2.7
Sherman Matthew L

EVP & Chief Medical Officer

Officer
1,655 -1.9%
14.40
US$23,835 		1,655 -1.9% 14.40 US$23,835
2023-06-21 2023-06-16 S Sale
3.6
Flynn Daniel Lee

Chief Scientific Officer

Officer
1,655 -2.8%
14.40
US$23,835 		1,655 -2.8% 14.40 US$23,835
2023-06-21 2023-06-16 S Sale
2.8
Pitman Jama

See Remarks

Officer
1,238 -2.7%
14.40
US$17,829 		1,238 -2.7% 14.40 US$17,829
2023-06-12 2023-06-08 B Purchase
1.5
Friedman Franklin Stuart
Non-Executive Director
10,000 +inf%
13.88
US$138,828 		10,000 +inf% 13.88 US$138,828
2023-05-12 2023-05-10 B Purchase
1.6
Walsh Dennis Leo
Non-Executive Director
11,000 +inf%
13.86
US$152,416 		11,000 +inf% 13.86 US$152,416
2023-03-23 2023-03-21 PlS Planned sale
3.7
Hoerter Steven L.

President and CEO

Executive Director
7,500 -100.0%
15.57
US$116,782 		7,500 -100.0% 15.57 US$116,782
2023-02-17 2023-02-16 S Sale
2.3
Martin Daniel C.

Chief Commercial Officer

Officer
1,159 -1.9%
15.10
US$17,500 		1,159 -1.9% 15.10 US$17,500
2023-02-17 2023-02-16 S Sale
2.9
Kelly Thomas Patrick

Chief Financial Officer

Officer
1,370 -2.3%
15.10
US$20,686 		1,370 -2.3% 15.10 US$20,686
2023-02-17 2023-02-16 S Sale
3.6
Flynn Daniel Lee

Chief Scientific Officer

Officer
1,370 -2.3%
15.10
US$20,686 		1,370 -2.3% 15.10 US$20,686
2023-02-17 2023-02-16 S Sale
2.7
Sherman Matthew L

EVP & Chief Medical Officer

Officer
971 -1.1%
15.10
US$14,661 		971 -1.1% 15.10 US$14,661
2023-02-17 2023-02-16 S Sale
2.8
Pitman Jama

See Remarks

Officer
1,159 -2.5%
15.10
US$17,500 		1,159 -2.5% 15.10 US$17,500
2023-02-16 2023-02-14 PlS Planned sale
3.7
Hoerter Steven L.

President and CEO

Executive Director
30,045 -80.0%
16.00
US$480,720 		30,045 -80.0% 16.00 US$480,720
2023-01-24 2023-01-24 B Purchase
2.0
Brightstar Associates LLC
Large shareholder
1,666,666 +9.2%
18.00
US$29,999,988 		1,666,666 +9.2% 18.00 US$29,999,988
2023-01-19 2023-01-17 PlS Planned sale
2.7
Sherman Matthew L

EVP & Chief Medical Officer

Officer
2,403 -3.2%
21.24
US$51,043 		2,403 -3.2% 21.24 US$51,043
2023-01-19 2023-01-17 PlS Planned sale
2.3
Martin Daniel C.

Chief Commercial Officer

Officer
1,603 -3.2%
21.24
US$34,050 		1,603 -3.2% 21.24 US$34,050
2023-01-19 2023-01-17 S Sale
2.9
Kelly Thomas Patrick

Chief Financial Officer

Officer
2,403 -5.2%
21.24
US$51,043 		2,403 -5.2% 21.24 US$51,043
2023-01-19 2023-01-17 S Sale
2.8
Pitman Jama

See Remarks

Officer
1,603 -4.4%
21.24
US$34,050 		1,603 -4.4% 21.24 US$34,050
2023-01-19 2023-01-17 S Sale
3.6
Flynn Daniel Lee

Chief Scientific Officer

Officer
2,403 -5.2%
21.24
US$51,043 		2,403 -5.2% 21.24 US$51,043
2022-10-05 2022-10-03 S Sale
2.7
Sherman Matthew L

EVP & Chief Medical Officer

Officer
2,587 -3.4%
18.73
US$48,455 		2,587 -3.4% 18.73 US$48,455
2022-06-21 2022-06-16 S Sale
2.9
Kelly Thomas Patrick

Chief Financial Officer

Officer
1,768 -3.7%
10.75
US$19,006 		1,768 -3.7% 10.75 US$19,006
2022-06-21 2022-06-16 S Sale
3.6
Flynn Daniel Lee

Chief Scientific Officer

Officer
1,768 -3.7%
10.75
US$19,006 		1,768 -3.7% 10.75 US$19,006
2022-06-21 2022-06-16 PlS Planned sale
2.7
Sherman Matthew L

EVP & Chief Medical Officer

Officer
1,768 -2.2%
10.75
US$19,006 		1,768 -2.2% 10.75 US$19,006
2022-06-21 2022-06-16 PlS Planned sale
2.3
Martin Daniel C.

Chief Commercial Officer

Officer
1,311 -2.6%
10.75
US$14,093 		1,311 -2.6% 10.75 US$14,093
2022-06-21 2022-06-16 S Sale
2.8
Pitman Jama

See Remarks

Officer
1,298 -3.4%
10.75
US$13,954 		1,298 -3.4% 10.75 US$13,954
2022-04-29 2022-04-29 B Purchase
2.0
Brightstar Associates LLC
Large shareholder
1,478,978 +8.9%
10.00
US$14,789,780 		1,478,978 +8.9% 10.00 US$14,789,780
2022-02-18 2022-02-16 S Sale
2.7
Sherman Matthew L

EVP & Chief Medical Officer

Officer
984 -1.3%
9.05
US$8,905 		984 -1.3% 9.05 US$8,905
2022-02-18 2022-02-16 S Sale
2.3
Martin Daniel C.

Chief Commercial Officer

Officer
1,146 -2.3%
9.05
US$10,371 		1,146 -2.3% 9.05 US$10,371
2022-02-18 2022-02-16 S Sale
3.6
Flynn Daniel Lee

Chief Scientific Officer

Officer
1,366 -2.8%
9.05
US$12,362 		1,366 -2.8% 9.05 US$12,362
2022-02-18 2022-02-16 S Sale
2.9
Kelly Thomas Patrick

Chief Financial Officer

Officer
1,368 -2.8%
9.05
US$12,380 		1,368 -2.8% 9.05 US$12,380
2022-02-18 2022-02-16 S Sale
2.8
Pitman Jama

See Remarks

Officer
1,146 -2.9%
9.05
US$10,371 		1,146 -2.9% 9.05 US$10,371
2021-10-06 2021-10-04 PlS Planned sale
2.7
Sherman Matthew L

EVP & Chief Medical Officer

Officer
2,659 -5.5%
33.17
US$88,199 		2,659 -5.5% 33.17 US$88,199
2021-05-05 2021-05-03 PlS Planned sale
Taylor Michael Douglas
Non-Executive Director
300 -100.0%
46.75
US$14,025 		300 -100.0% 46.75 US$14,025
2021-05-05 2021-05-03 PlS Planned sale
Taylor Michael Douglas
Non-Executive Director
7,700 -96.2%
46.07
US$354,718 		7,700 -96.2% 46.07 US$354,718
2021-04-21 2021-04-20 PlS Planned sale
0.6
Bristol James Arthur
Non-Executive Director
1,700 -100.0%
45.60
US$77,514 		1,700 -100.0% 45.60 US$77,514
2021-04-21 2021-04-19 PlS Planned sale
0.6
Bristol James Arthur
Non-Executive Director
1,300 -100.0%
46.66
US$60,662 		1,300 -100.0% 46.66 US$60,662
2021-04-21 2021-04-19 PlS Planned sale
0.6
Bristol James Arthur
Non-Executive Director
4,000 -75.5%
46.13
US$184,518 		4,000 -75.5% 46.13 US$184,518
2021-04-14 2021-04-12 PlS Planned sale
0.6
Bristol James Arthur
Non-Executive Director
5,217 -100.0%
44.09
US$230,040 		5,217 -100.0% 44.09 US$230,040
2021-04-14 2021-04-12 PlS Planned sale
0.6
Bristol James Arthur
Non-Executive Director
9,483 -64.5%
43.70
US$414,370 		9,483 -64.5% 43.70 US$414,370
2021-04-06 2021-04-01 PlS Planned sale
Taylor Michael Douglas
Non-Executive Director
906 -100.0%
46.72
US$42,328 		906 -100.0% 46.72 US$42,328
2021-04-06 2021-04-01 PlS Planned sale
Taylor Michael Douglas
Non-Executive Director
4,994 -84.6%
45.69
US$228,169 		4,994 -84.6% 45.69 US$228,169
2021-04-06 2021-04-01 PlS Planned sale
Taylor Michael Douglas
Non-Executive Director
2,100 -26.2%
44.80
US$94,074 		2,100 -26.2% 44.80 US$94,074
2021-03-03 2021-03-01 PlS Planned sale
Taylor Michael Douglas
Non-Executive Director
1,104 -100.0%
44.68
US$49,324 		1,104 -100.0% 44.68 US$49,324
2021-03-03 2021-03-01 PlS Planned sale
Taylor Michael Douglas
Non-Executive Director
6,896 -86.2%
43.94
US$302,983 		6,896 -86.2% 43.94 US$302,983
2021-02-18 2021-02-16 S Sale
2.7
Sherman Matthew L

EVP & Chief Medical Officer

Officer
132 -0.4%
48.87
US$6,451 		132 -0.4% 48.87 US$6,451
2021-02-18 2021-02-16 S Sale
3.6
Flynn Daniel Lee

Chief Scientific Officer

Officer
508 -7.2%
48.87
US$24,826 		508 -7.2% 48.87 US$24,826
2021-02-18 2021-02-16 S Sale
2.9
Kelly Thomas Patrick

Chief Financial Officer

Officer
524 -7.4%
48.87
US$25,608 		524 -7.4% 48.87 US$25,608
2021-02-03 2021-02-01 PlS Planned sale
Taylor Michael Douglas
Non-Executive Director
800 -100.0%
45.96
US$36,770 		800 -100.0% 45.96 US$36,770
2021-02-03 2021-02-01 PlS Planned sale
Taylor Michael Douglas
Non-Executive Director
4,518 -85.0%
45.64
US$206,188 		4,518 -85.0% 45.64 US$206,188
2021-02-03 2021-02-01 PlS Planned sale
Taylor Michael Douglas
Non-Executive Director
2,682 -33.5%
44.34
US$118,915 		2,682 -33.5% 44.34 US$118,915
2021-01-20 2021-01-15 PlS Planned sale
0.6
Bristol James Arthur
Non-Executive Director
600 -100.0%
51.11
US$30,666 		600 -100.0% 51.11 US$30,666
2021-01-20 2021-01-15 PlS Planned sale
0.6
Bristol James Arthur
Non-Executive Director
6,400 -91.4%
50.21
US$321,373 		6,400 -91.4% 50.21 US$321,373
2021-01-06 2021-01-04 PlS Planned sale
Taylor Michael Douglas
Non-Executive Director
2,794 -100.0%
57.37
US$160,294 		2,794 -100.0% 57.37 US$160,294
Explore more

More insider trading research around Deciphera Pharmaceuticals Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America